Mavacamten

Mavacamten

Clinical data
Trade names	Camzyos
Other names	MYK-461
License data	US DailyMed: Mavacamten
Pregnancy category	AU: D
Routes of administration	By mouth
Drug class	Cardiac myosin inhibitor
ATC code	C01EB24 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only US: ℞-only
Identifiers
IUPAC name 6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione
CAS Number	1642288-47-8
PubChem CID	117761397
DrugBank	DB14921
UNII	QX45B99R3J
KEGG	D12265
Chemical and physical data
Formula	C15H19N3O2
Molar mass	273.336 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)N1C(=O)NC(N[C@@H](C)C2=CC=CC=C2)=CC1=O
InChI InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1 Key:RLCLASQCAPXVLM-NSHDSACASA-N

Mavacamten, sold under the brand name Camzyos, is a medication used to treat obstructive hypertrophic cardiomyopathy.

Mavacamten is a cardiac myosin inhibitor. It was developed by MyoKardia, a subsidiary of Bristol Myers Squibb.

Mavacamten was approved for medical use in the United States in April 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Medical uses

Mavacamten is indicated for the treatment of adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.

History

Mavacamten was granted orphan drug designation by the U.S. Food and Drug Administration (FDA).

Society and culture

Legal status

On 26 April 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Camzyos, intended for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The applicant for this medicinal product is Bristol-Myers Squibb Pharma EEIG.

Names

Mavacamten is the international nonproprietary name (INN).

Further reading

• Xie J, Wang Y, Xu Y, Fine JT, Lam J, Garrison LP (2022). "Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial". Journal of Medical Economics. 25 (1): 51–58. doi:10.1080/13696998.2021.2011301. PMID 34907813.

External links

• Clinical trial number NCT03470545 for "Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM)" at ClinicalTrials.gov